Compare iShares MSCI India ETF (INDA) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI India ETF vs Smith & Nephew plc — how do they compare? iShares MSCI India ETF trades at $49.94, while Smith & Nephew plc trades at $30.23 (market cap $12.54B). The key difference: Smith & Nephew plc pays a 2.65% dividend while iShares MSCI India ETF pays none, and iShares MSCI India ETF is trading nearer its 52-week high, Smith & Nephew plc nearer its low. Which is the better fit depends on your goals.
| INDA | SNN | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $55.29 | $38.70 |
52-Week Low | $45.42 | $28.73 |
Market Cap | — | $12.54B |
Enterprise Value | — | $15.57B |
Dividend Yield | — | 2.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INDA trades at $49.95, down 0.38% with a bullish technical signal supported by moving averages. The ETF tracks India's market, which grew 7.8% in Q1 2026 (CNBC, June 5, 2026), but faces headwinds from foreign outflows and sector-specific challenges in pharma and IT. Key support and resistance cluster around $50.
Outlook remains mixed: India's strong economic growth offers long-term potential, but near-term risks include Middle East disruptions affecting exports (Reuters, August 4, 2026) and AI-driven pressure on IT firms. Institutional sentiment is cautious amid foreign capital rotation.
SNN trades at $29.87, down 0.71% on the day, with a bearish technical signal. The company reported Q2 2026 revenue growth of 1.6%, below expectations, leading to a reduced full-year outlook. Fundamentals show improvement with 2025 revenue of $6.16B and net income of $625M, yielding a 10.08% margin, though recent earnings have been mixed. The balance sheet remains solid with $619M in cash and a debt-to-asset ratio of 29.75% for 2025.
The outlook is cautious due to near-term operational weakness, particularly in U.S. Orthopaedics, offset by innovation in robotics and wound care. Risks include execution challenges and competitive pressures, while analyst sentiment is predominantly Hold. The stock's valuation appears reasonable with a P/E of 20.41, but growth catalysts are needed for significant upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares MSCI India ETF
INDA tracks the MSCI India Index, providing broad exposure to large and mid-cap companies in the Indian stock market. It is structurally dominated by the financials, information technology, and energy sectors, serving as a core instrument for investors seeking a single-country view of India's long-term economic growth.
Read more on INDA →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
